×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Myrna Chandler Goldstein
While the surgeon suggested I have a lumpectomy followed by radiation treatments, I had already made my decision. I requested a double mastectomy without any type of reconstruction. Why would I pursue such a radical alternative? In this post, I explain my choice. 
Alexandra Guadagno
From Trump’s executive order regarding drug prices to today’s top performers and athletes, here’s what is making headlines in the cancer space this week.
Katie Kosko
Patients with renal cell carcinoma who were treated with a targeted therapy lived three months longer than people who received older treatments.
Jessica Stringer
There are many instances I could tell you about when and how God carried us through my son’s battle with testicular cancer. The right things happened at the most opportune times.
Alexandra Guadagno
CURE® asked its readers: “What is one thing you wish you could tell your younger, pre-cancer self?”
Lori Luedtke
As I have gone through this cancer journey, I have realized that people don’t know what to say or do when a loved one has cancer. I can speak out on my firsthand experiences and offer some advice.
Jessica Skarzynski
The second recipe in our Summer Snacktime Series with the John Theurer Cancer Center works as a creative "meatless" meal or savory snack.
Trisha Ready
Music can help people tolerate and distract from emotional and physiological pain while going through cancer treatments and scans.
Alexandra Guadagno
The combination use of Darzalex in combination with Revlimid, Velcade and Ozurdex demonstrated a higher percentage of stringent complete responses among transplant eligible, newly diagnosed patients with multiple myeloma.
Katie Kosko
The Food and Drug Administration granted CLR 131, a targeted, molecular radiotherapy, a fast track designation.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other